OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
Prithviraj Bose, Lucia Masárová, Srđan Verstovšek
Cancers (2020) Vol. 12, Iss. 10, pp. 2891-2891
Open Access | Times Cited: 14
Prithviraj Bose, Lucia Masárová, Srđan Verstovšek
Cancers (2020) Vol. 12, Iss. 10, pp. 2891-2891
Open Access | Times Cited: 14
Showing 14 citing articles:
Momelotinib: an emerging treatment for myelofibrosis patients with anemia
Helen T. Chifotides, Prithviraj Bose, Srđan Verstovšek
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 63
Helen T. Chifotides, Prithviraj Bose, Srđan Verstovšek
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 63
Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials
Dhananjay Yadav, Minseok Kwak, Pallavi Chauhan, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 909-922
Closed Access | Times Cited: 45
Dhananjay Yadav, Minseok Kwak, Pallavi Chauhan, et al.
Seminars in Cancer Biology (2022) Vol. 86, pp. 909-922
Closed Access | Times Cited: 45
Real-world clinical outcomes of patients with myelofibrosis treated with ruxolitinib: a medical record review
Francesco Passamonti, Florian H. Heidel, Rohan Parikh, et al.
Future Oncology (2022) Vol. 18, Iss. 18, pp. 2217-2231
Open Access | Times Cited: 16
Francesco Passamonti, Florian H. Heidel, Rohan Parikh, et al.
Future Oncology (2022) Vol. 18, Iss. 18, pp. 2217-2231
Open Access | Times Cited: 16
SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis
Helen T. Chifotides, Lucia Masárová, Srđan Verstovšek
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 4, pp. 219-231
Open Access | Times Cited: 7
Helen T. Chifotides, Lucia Masárová, Srđan Verstovšek
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 4, pp. 219-231
Open Access | Times Cited: 7
Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms
Yammy Yung, Emily Lee, Hiutung Chu, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 659-659
Open Access | Times Cited: 12
Yammy Yung, Emily Lee, Hiutung Chu, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 659-659
Open Access | Times Cited: 12
SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis
Helen T. Chifotides, Prithviraj Bose, Lucia Masárová, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 22, Iss. 4, pp. 210-223
Closed Access | Times Cited: 11
Helen T. Chifotides, Prithviraj Bose, Lucia Masárová, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 22, Iss. 4, pp. 210-223
Closed Access | Times Cited: 11
The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms
Elisa Parciante, Cosimo Cumbo, Luisa Anelli, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4860-4860
Open Access | Times Cited: 2
Elisa Parciante, Cosimo Cumbo, Luisa Anelli, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4860-4860
Open Access | Times Cited: 2
Novel therapeutics for myelofibrosis
Sung‐Eun Lee
Blood Research (2023) Vol. 58, Iss. S1, pp. S13-S19
Open Access | Times Cited: 2
Sung‐Eun Lee
Blood Research (2023) Vol. 58, Iss. S1, pp. S13-S19
Open Access | Times Cited: 2
Inhibitors of the Sialidase NEU3 as Potential Therapeutics for Fibrosis
Tejas R. Karhadkar, Wensheng Chen, Darrell Pilling, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 239-239
Open Access | Times Cited: 4
Tejas R. Karhadkar, Wensheng Chen, Darrell Pilling, et al.
International Journal of Molecular Sciences (2022) Vol. 24, Iss. 1, pp. 239-239
Open Access | Times Cited: 4
Combination of ligand‑based and structure‑based virtual screening for the discovery of novel Janus kinase 2 inhibitors against philadelphia-negative myeloproliferative neoplasms
Binyou Wang, Jianmin Guo, Bo Chen, et al.
Molecular Diversity (2024)
Closed Access
Binyou Wang, Jianmin Guo, Bo Chen, et al.
Molecular Diversity (2024)
Closed Access
JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions
Xiaofeng Liu, Binyou Wang, Yuan Liu, et al.
Molecular Diversity (2023)
Closed Access | Times Cited: 1
Xiaofeng Liu, Binyou Wang, Yuan Liu, et al.
Molecular Diversity (2023)
Closed Access | Times Cited: 1
Philadelphia-Negative MPN: A Molecular Journey, from Hematopoietic Stem Cell to Clinical Features
Valentina Giai, Carolina Secreto, Roberto Freilone, et al.
Medicina (2021) Vol. 57, Iss. 10, pp. 1043-1043
Open Access | Times Cited: 2
Valentina Giai, Carolina Secreto, Roberto Freilone, et al.
Medicina (2021) Vol. 57, Iss. 10, pp. 1043-1043
Open Access | Times Cited: 2
In the Pipeline: Emerging Therapy for Classical Ph-Negative MPNs
Harinder Gill, Yammy Yung
(2023), pp. 607-623
Closed Access
Harinder Gill, Yammy Yung
(2023), pp. 607-623
Closed Access
Potential New Therapeutic Approaches for Myelofibrosis
Helen T. Chifotides, Srđan Verstovšek
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 21, pp. S130-S133
Closed Access
Helen T. Chifotides, Srđan Verstovšek
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 21, pp. S130-S133
Closed Access
